Senile dementia associated with amyloid β protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-ε4 allele

2000 ◽  
Vol 100 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Rubén Vidal ◽  
Miguel Calero ◽  
Pedro Piccardo ◽  
Martin R. Farlow ◽  
Frederick W. Unverzagt ◽  
...  
1995 ◽  
Vol 1 (2) ◽  
pp. 135-137 ◽  
Author(s):  
James A.R. Nicoll ◽  
Gareth W. Roberts ◽  
David I. Graham

1999 ◽  
Vol 97 (1) ◽  
pp. 82-84 ◽  
Author(s):  
T. Arai ◽  
Kenji Ikeda ◽  
Haruhiko Akiyama ◽  
Chie Haga ◽  
Mihoko Usami ◽  
...  

CNS Spectrums ◽  
2008 ◽  
Vol 13 (S3) ◽  
pp. 3-3
Author(s):  
Stephen Salloway

In 1906, the German physician Alois Alzheimer provided the first description of the “serious and peculiar disease” of mental deterioration that would later on take his name. Alzheimer described the classic pathology of neuritic plaques and neurofibrillary tangles in an affected patient. Since that time, understanding of Alzheimer's disease (AD) has progressed substantially, although the ability to influence disease progression has not progressed as rapidly. It is likely that over the next decade these advances will lead to earlier diagnosis and development of disease-modifying treatments for AD.It is known that two variants of AD exist: a rare hereditary form and a more prevalent sporadic form. As with many neurodegenerative diseases, early clues to the pathology of AD came from the inherited form of the disease. Hereditary links include mutations of the amyloid precursor protein (APP) and the presenilins, both of which are integrally involved in the cascade of events that leads to the deposition of the 42-amino-acid amyloid β protein and the eventual cell death responsible for AD.


PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e41636 ◽  
Author(s):  
Cheryl A. Hawkes ◽  
Patrick M. Sullivan ◽  
Sarah Hands ◽  
Roy O. Weller ◽  
James A. R. Nicoll ◽  
...  

2021 ◽  
Vol 22 (4) ◽  
pp. 2099
Author(s):  
Nikol Jankovska ◽  
Tomas Olejar ◽  
Radoslav Matej

Alzheimer’s disease (AD) and sporadic Creutzfeldt–Jakob disease (sCJD) are both characterized by extracellular pathologically conformed aggregates of amyloid proteins—amyloid β-protein (Aβ) and prion protein (PrPSc), respectively. To investigate the potential morphological colocalization of Aβ and PrPSc aggregates, we examined the hippocampal regions (archicortex and neocortex) of 20 subjects with confirmed comorbid AD and sCJD using neurohistopathological analyses, immunohistochemical methods, and confocal fluorescent microscopy. Our data showed that extracellular Aβ and PrPSc aggregates tended to be, in most cases, located separately, and “compound” plaques were relatively rare. We observed PrPSc plaque-like structures in the periphery of the non-compact parts of Aβ plaques, as well as in tau protein-positive dystrophic structures. The AD ABC score according to the NIA-Alzheimer’s association guidelines, and prion protein subtype with codon 129 methionine–valine (M/V) polymorphisms in sCJD, while representing key characteristics of these diseases, did not correlate with the morphology of the Aβ/PrPSc co-aggregates. However, our data showed that PrPSc aggregation could dominate during co-aggregation with non-compact Aβ in the periphery of Aβ plaques.


2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Woo Shik Shin ◽  
Jing Di ◽  
Qin Cao ◽  
Binsen Li ◽  
Paul M. Seidler ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


The Lancet ◽  
1992 ◽  
Vol 339 (8787) ◽  
pp. 245 ◽  
Author(s):  
Hilkka Soininen ◽  
Stina Syrjänen ◽  
Outi Heinonen ◽  
Heikki Neittaanmäki ◽  
Riitta Miettinen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document